IN THE CLAIMS:

Please cancel claim 2 without prejudice or disclaimer of the subject matter contained therein.

Please amend the claims as follows:

1.   (Amended) An isolated human [angiogenesis-associated] protein having anti-angiogenic activity and that is a receptor for an [capable of binding an] N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5.

3.   (Amended) The protein of claim 1 [or 2] comprising an amino acid sequence having [at least approximately 80%] sequence homology equal to or greater than 80% [, preferably approximately 90% sequence homology, more preferably approximately 95% sequence homology and most preferably approximately 98% sequence homology] to SEQ ID Nos: 2, 3 or 4.

JUN 27 2000

28.   (Amended) A method for treating an angiogenesis-related disease or disorder comprising administering an effective amount of [The] the proteins[,] or peptides [or compounds] of any one of claims 1 [to 8 and 26 for use as a medicament] and 3-8 to a patient in need thereof.

29.   (Amended) A method for manufacturing a composition for the treatment of an angiogenesis-related disease comprising mixing [Use of the proteins,] the peptides [or compounds] according to

any one of claims 1 [to 8 and 26 in the manufacture of a medicament directed towards an angiogenesis-related disease or disorder] and 3-8 with a suitable pharmaceutical carrier.

30. (Amended) A [pharmaceutical preparation] composition comprising a protein[,] or peptide [or compound] according to any one of claims 1 and 3-8 [to 8 and 26] together with a pharmaceutically acceptable carrier.

Please add the following new claims:

--31.   The protein of claim 3, wherein the amino acid sequence has approximately 90% sequence homology to SEQ ID Nos: 2, 3 or 4.

32. The protein of claim 3, wherein the amino acid sequence has approximately 95% sequence homology to SEQ ID Nos: 2, 3 or 4.

33. The protein of claim 3, wherein the amino acid sequence has approximately 98% sequence homology to SEQ ID Nos: 2, 3 or 4.--

3